Your browser doesn't support javascript.
loading
Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation.
Pagliuca, Simona; Prata, Pedro Henrique; Xhaard, Aliénor; Frieri, Camilla; Giannoni, Livia; Sutra Del Galy, Aurelien; Brignier, Anne; Sicre de Fontbrune, Flore; Michonneau, David; Dhedin, Nathalie; Peffault de Latour, Régis; Socié, Gérard; Robin, Marie.
Afiliación
  • Pagliuca S; Assistance Publique Hôpitaux des Paris, Saint Louis Hospital, Hematology and Transplantation Unit, Paris, France. smnpag@gmail.com.
  • Prata PH; Université de Paris, Paris, France. smnpag@gmail.com.
  • Xhaard A; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, Ohio, United States. smnpag@gmail.com.
  • Frieri C; Assistance Publique Hôpitaux des Paris, Saint Louis Hospital, Hematology and Transplantation Unit, Paris, France.
  • Giannoni L; Assistance Publique Hôpitaux des Paris, Saint Louis Hospital, Hematology and Transplantation Unit, Paris, France.
  • Sutra Del Galy A; Assistance Publique Hôpitaux des Paris, Saint Louis Hospital, Hematology and Transplantation Unit, Paris, France.
  • Brignier A; Université de Paris, Paris, France.
  • Sicre de Fontbrune F; Department of Hematology and Transplantation, Federico II University, Naples, Italy.
  • Michonneau D; Assistance Publique Hôpitaux des Paris, Saint Louis Hospital, Hematology and Transplantation Unit, Paris, France.
  • Dhedin N; Assistance Publique Hôpitaux des Paris, Saint Louis Hospital, Hematology and Transplantation Unit, Paris, France.
  • Peffault de Latour R; Université de Paris, Paris, France.
  • Socié G; Assistance Publique Hôpitaux des Paris, Saint Louis Hospital, Therapeutic Apheresis Unit, Paris, France.
  • Robin M; Assistance Publique Hôpitaux des Paris, Saint Louis Hospital, Hematology and Transplantation Unit, Paris, France.
Bone Marrow Transplant ; 56(1): 38-49, 2021 01.
Article en En | MEDLINE | ID: mdl-32587336
ABSTRACT
Steroid-refractory graft versus host disease (GVHD) represents a fearsome complication after allogeneic hematopoietic stem cell transplantation (HSCT). We conducted a retrospective study on outcomes and risk factors associated with acute and chronic steroid-refractory GVHD in a large cohort of 1207 patients receiving HSCT in Saint Louis Hospital between 2007 and 2017. Among patients who developed an acute and/or a chronic GVHD, the cumulative incidences of acute and chronic steroid-refractory disease were 31% and 48%, respectively, at day +100 and 1-year post-HSCT. Through a multivariable analysis we selected several risk factors associated with the development of a steroid-refractory disease. For acute GVHD steroid refractoriness, we identified (1) a very high disease risk index, (2) an unrelated donor, (3) the absence of in vivo T-depletion as GVHD prophylaxis, and (4) a reduced intensity conditioning regimen. For chronic GVHD, (1) the use of peripheral blood stem cells, (2) unrelated donors, and (3) absence of in vivo T-depletion were more likely associated with a steroid-refractory disease. After the construction of a multistate dynamic model, we found that the probability of being alive without relapse after the resolution of all GVHD episodes was about 36% in the long term.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article